A different methylation profile of circadian genes promoter in breast cancer patients according to clinicopathological features

References

• Alexander M, Burch JB, Steck SE, Chen C-F, Hurley TG, Cavicchia P, Shivappa N, Guess J, Zhang H, Youngstedt SD, et al. 2017 Feb. Case-control study of candidate gene methylation and adenomatous polyp formation. Int J Colorectal Dis. 32(2):183–192.
   PubMed Web of Science ®Google Scholar
• Bai Z, Gust R. 2009 Mar. Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim). 342(3):133–149.
   PubMed Web of Science ®Google Scholar
• Blakeman V, Williams JL, Meng QJ, Streuli CH. 2016 Sep. Circadian clocks and breast cancer. Breast Cancer Res. 18(1):89.
   PubMedGoogle Scholar
• Bonde JP, Hansen J, Kolstad HA, Mikkelsen S, Olsen JH, Blask DE, Härmä M, Kjuus H, de Koning HJ, Olsen J, et al. 2012 Jul. Work at night and breast cancer–report on evidence-based options for preventive actions. Scand J Work Environ Health. 38(4):380–390.
   PubMed Web of Science ®Google Scholar
• Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB, Simon MC, Takahashi JS, Bradfield CA. 2000 Dec. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell. 103(7):1009–1017.
   PubMed Web of Science ®Google Scholar
• Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S. 2014 Mar. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 34(3):1071–1077.
   PubMed Web of Science ®Google Scholar
• Chen ST, Choo KB, Hou MF, Yeh K-T, Kuo S-J, Chang J-G. 2005 Jul. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 26(7):1241–1246.
   PubMed Web of Science ®Google Scholar
• Clark BZ, Onisko A, Assylbekova B, Li, X., Bhargava, R., Dabbs, D.J. 2018 Oct. Breast cancer global tumor biomarkers: a quality assurance study of intratumoral heterogeneity. Mod Pathol. 32(3):354–366.
   Web of Science ®Google Scholar
• DeVaux RS, Herschkowitz JI. 2018 Oct. Beyond DNA: the role of epigenetics in the premalignant progression of breast cancer. J Mammary Gland Biol Neoplasia. 23(4):223–235.
   PubMed Web of Science ®Google Scholar
• Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz L-A, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, et al. 2011 Oct 1. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71(19):6195–6207. doi:10.1158/0008-5472.CAN-11-1630.
   PubMed Web of Science ®Google Scholar
• Flavahan WA, Gaskell E, Bernstein BE. 2017 Jul 21. Epigenetic plasticity and the hallmarks of cancer. Science. 357(6348). doi:10.1126/science.aal2380.
   PubMed Web of Science ®Google Scholar
• Franzese E, Nigri G. 2007 Apr-Jun. Night work as a possible risk factor for breast cancer in nurses. Correlation between the onset of tumors and alterations in blood melatonin levels. Prof Inferm. 60(2):89–93.
   PubMedGoogle Scholar
• Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. 2012 Dec. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Mol Carcinog. 51(12):923–929.
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C. 2002 Oct. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 111(1):41–50.
   PubMed Web of Science ®Google Scholar
• Gery S, Koeffler HP. 2007. The role of circadian regulation in cancer. Cold Spring Harbor Symp. 72:459–464.
   PubMedGoogle Scholar
• Gery S, Koeffler HP. 2010 Mar. Circadian rhythms and cancer. Cell Cycle. 9(6):1097–1103.
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. 2006 May. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 22(3):375–382.
   PubMed Web of Science ®Google Scholar
• Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. 2007 Dec. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 26(57):7916–7920.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y. 2010a Feb. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 70(4):1459–1468.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Ba Y, Zhu Y. 2008 Sep. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res. 6(9):1461–1468.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y. 2010b Apr. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer Prev Res. 3(4):539–548.
   PubMed Web of Science ®Google Scholar
• Hsu MC, Huang CC, Choo KB, Huang C-J. 2007 Aug 17. Uncoupling of promoter methylation and expression of Period1 in cervical cancer cells. Biochem Biophys Res Commun. 360(1):257–262. doi:10.1016/j.bbrc.2007.06.042.
   PubMed Web of Science ®Google Scholar
• Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg F. 2006 Jul. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 97(7):589–596.
   PubMed Web of Science ®Google Scholar
• Kuo SJ, Chen ST, Yeh KT, Hou M-F, Chang Y-S, Hsu NC, Chang J-G. 2009 Apr. Disturbance of circadian gene expression in breast cancer. Virchows Arch. 454(4):467–474.
   PubMed Web of Science ®Google Scholar
• Lesicka M, Jablonska E, Wieczorek E, Seroczyńska B, Siekierzycka A, Skokowski J, Kalinowski L, Wąsowicz W, Reszka E, Coleman WB. 2018 Jun. Altered circadian genes expression in breast cancer tissue according to the clinical characteristics [Article]. PLoS One. 13(6):15.
   Web of Science ®Google Scholar
• Li L, Lee KM, Han W, Choi J-Y, Lee J-Y, Kang GH, Park SK, Noh D-Y, Yoo K-Y, Kang D. 2010 Nov 1. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet. 19(21):4273–4277. doi:10.1093/hmg/ddq351.
   PubMed Web of Science ®Google Scholar
• Lin YM, Chang JH, Yeh KT, Yang M-Y, Liu T-C, Lin S-F, Su -W-W, Chang J-G. 2008 Dec. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 47(12):925–933.
   PubMed Web of Science ®Google Scholar
• Liu L, Shen H, Wang Y. 2017 Aug 12. CRY2 is suppressed by FOXM1 mediated promoter hypermethylation in breast cancer. Biochem Biophys Res Commun. 490(1):44–50. doi:10.1016/j.bbrc.2017.06.003.
   PubMedGoogle Scholar
• Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y. 2015 May. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications. Tumour Biol. 36(5):3533–3539.
   PubMedGoogle Scholar
• Mohtat D, Susztak K. 2010 Sep. Fine tuning gene expression: the epigenome. Semin Nephrol. 30(5):468–476.
   PubMed Web of Science ®Google Scholar
• Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Lorenzo Bermejo J, et al. 2012 Nov. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology. 56(5):1817–1827.
   PubMed Web of Science ®Google Scholar
• Onishi Y. 2011 Feb. HSG cells, a model in the submandibular clock. Biosci Rep. 31(1):57–62.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Hanai S, Ohno T, Hara Y, Ishida N. 2008 May. Rhythmic SAF-A binding underlies circadian transcription of the Bmal1 gene. Mol Cell Biol. 28(10):3477–3488.
   PubMed Web of Science ®Google Scholar
• Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, et al. 2004 Aug 15. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res. 10(16):5349–5354. doi:10.1158/1078-0432.CCR-04-0555.
   PubMed Web of Science ®Google Scholar
• Polen KD, Gilboa SM, Hills S, Oduyebo T, Kohl KS, Brooks JT, Adamski A, Simeone RM, Walker AT, Kissin DM, et al. 2018 Jun 1. QuickStats: breast cancer death rates* among women aged 50-74 years, by race/ethnicity - national vital statistics system, United States, 2006 and 2016. Morb Mortal Wkly Rep. 67(21):614. doi:10.15585/mmwr.mm6731e2.
   PubMed Web of Science ®Google Scholar
• Rashmi S, Kamala S, Murthy SS, Kotha S, Rao YS, Chaudhary KV. 2018 Jul-Sep. Predicting the molecular subtype of breast cancer based on mammography and ultrasound findings. Indian J Radiol Imaging. 28(3):354–361.
   PubMed Web of Science ®Google Scholar
• Reszka E, Wieczorek E, Przybek M, Jabłońska E, Kałużny P, Bukowska-Damska A, Zienolddiny S, Pepłońska B. 2018. Circadian gene methylation in rotating-shift nurses: a cross-sectional study. Chronobiol Int. 35(1):111–121.
   PubMed Web of Science ®Google Scholar
• Samulin Erdem J, Skare O, Petersen-Overleir M, Notø HØ, Lie J-AS, Reszka E, Pepłońska B, Zienolddiny S. 2017. Mechanisms of breast cancer in shift workers: DNA methylation in five core circadian genes in nurses working night shifts. J Cancer. 8(15):2876–2884.
   PubMed Web of Science ®Google Scholar
• Satou R, Sugihara N, Ishizuka Y, Matsukubo T, Onishi Y. 2013 Oct 25. DNA methylation of the BMAL1 promoter. Biochem Biophys Res Commun. 440(3):449–453. doi:10.1016/j.bbrc.2013.09.124.
   PubMed Web of Science ®Google Scholar
• Shih MC, Yeh KT, Tang KP, Chen J-C, Chang J-G. 2006 Oct. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog. 45(10):732–740.
   PubMed Web of Science ®Google Scholar
• Stevens RG. 2005 Mar. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology. 16(2):254–258.
   PubMed Web of Science ®Google Scholar
• Takahashi JS, Hong HK, Ko CH, McDearmon EL. 2008 Oct. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 9(10):764–775.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Fernandez AF, Setien F, Ropero S, Ballestar E, Villanueva A, Yamamoto H, Imai K, Shinomura Y, Esteller M. 2009 Nov 1. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 69(21):8447–8454. doi:10.1158/0008-5472.CAN-09-0551.
   PubMed Web of Science ®Google Scholar
• Tomita T, Kurita R, Onishi Y. 2017 Jun 30. Epigenetic regulation of the circadian clock: role of 5-aza-2ʹ-deoxycytidine. Biosci Rep. 37(3). doi:10.1042/BSR20170053.
   PubMedGoogle Scholar
• Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. 2007 Oct. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia. 9(10):797–800.
   PubMed Web of Science ®Google Scholar
• Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, Hill SM. 2008 Mar 11. Period-2: a tumor suppressor gene in breast cancer. J Circadian Rhythms. 6:4. doi:10.1186/1740-3391-6-4.
   PubMedGoogle Scholar
• Yeh CM, Shay J, Zeng TC, Chou J-L, Huang TH-M, Lai H-C, Chan MWY. 2014 Nov. Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer. Int J Oncol. 45(5):2101–2107.
   PubMed Web of Science ®Google Scholar
• Yeh KT, Yang MY, Liu TC, Chen J-C, Chan W-L, Lin S-F, Chang J-G. 2005 May. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol. 206(1):111–120.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Stevens RG, Hoffman AE, Tjonneland A, Vogel UB, Zheng T, Hansen J. 2011 Dec. Epigenetic impact of long-term shiftwork: pilot evidence from circadian genes and whole-genome methylation analysis. Chronobiol Int. 28(10):852–861.
   PubMed Web of Science ®Google Scholar
• Zubidat AE, Fares B, Fares F, Haim A. 2018 Jan-Dec. Artificial light at night of different spectral compositions differentially affects tumor growth in Mice: interaction with melatonin and epigenetic pathways. Cancer Control. 25(1):1073274818812908.
   Web of Science ®Google Scholar